Browse studies

Find your next paid study

246 recruiting studies matching your filters

Newest first Highest paying

Phase 3

JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial

To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

Non-Small Cell Lung Cancer

Estimated

~$10 – $6,250

University of Texas Southwestern Medical CenterNCT02468024

Phase 1

A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in…

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Estimated

~$10 – $7,500

AstraZenecaNCT04686305

Phase 1

Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (…

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Estimated

~$10 – $7,500

NYU Langone HealthNCT05815173

Phase 2

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

This is an open-label, multicenter, randomized phase 2 trial for patients with tyrosine kinase inhibitor-naïve ALKrearranged advanced NSCLC. Subjects are initi…

Advanced Non-Small Cell Lung Cancer

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07415005

Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer

A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targ…

Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more

Estimated

~$10 – $750

University of Colorado, DenverNCT03042221

Phase 2

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

In this study circulating tumor DNA (ctDNA) blood testing is used to detect the residual blood cancer. If residual cancer using this blood test is detected the…

Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage INon-small Cell Lung Cancer Stage II+1 more

Estimated

~$10 – $6,250

Stanford UniversityNCT04585477